Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 7:22 PM
Ignite Modification Date: 2025-12-25 @ 5:02 PM
NCT ID: NCT01222403
Description: All solicited AEs and unsolicited AEs were collected from Day 1 to Day 4; all unsolicited SAEs, medically attended AEs, AEs leading to withdrawal from the study were collected from Day 1 to Day 28.
Frequency Threshold: 5
Time Frame: Throughout the study (Day 1 through Day 28).
Study: NCT01222403
Study Brief: A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Vantaflu_aTIV Subjects aged \>65 years received one dose of Vantaflu\_aTIV: investigational MF59-adjuvanted trivalent influenza vaccine. None None 0 379 155 379 View
Fluad_aTIV Subjects aged \>65 years received one dose of Fluad\_aTIV: investigational MF59-adjuvanted trivalent influenza vaccine. None None 0 386 163 386 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Fatigue SYSTEMATIC_ASSESSMENT General disorders MedDRA (17.1) View
Injection site pain SYSTEMATIC_ASSESSMENT General disorders MedDRA (17.1) View
Injection site swelling SYSTEMATIC_ASSESSMENT General disorders MedDRA (17.1) View
Injection site erythema SYSTEMATIC_ASSESSMENT General disorders MedDRA (17.1) View
Chills SYSTEMATIC_ASSESSMENT General disorders MedDRA (17.1) View
Myalgia SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (17.1) View
Arthralgia SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (17.1) View
Headache SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (17.1) View